Published: Aug-2021 | Format: PDF | Market Research Store | Number of pages: 190 | Code: MRS - 828612
The global demand for the Adjuvant market was calculable at USD 760.3 Million in 2020 and is anticipated to come up with revenue of around USD 1,800.6 Million by finish of 2026, growing at a CAGR of around 11.1% between 2021 and 2026.
An adjuvant is an element used in several vaccines that helps creates a powerful immune response in individuals getting the vaccine. Simply, adjuvant helps out vaccines work better. Many vaccines made from killed or damaged germs include natural adjuvant and help out the body generate a strong protective immune response. Moreover, adjuvant helps the body to produce an immune response strong enough to protect the person from the disease; a person is being vaccinated against. Adjuvanted vaccines can cause general reactions (such as swelling, redness, and pain at the injection site) and more systemic reactions (such as fever and body aches) than non-adjuvanted vaccines.
Adjuvant oncology care is a part of cancer treatments, that requires further cancer treatment after the achievement of the primary treatment and its main aim is to lessen the risk of cancer. Adjuvant therapy includes targeted therapy, chemotherapy, radiation therapy, biological therapy, and hormone therapy.
|REPORT SNAPSHOT & REPORTING DATA TIMEFRAME|
|Historical Date ( Actual Data)||2016 - 2020|
|Base Year Data||2020|
|Current Year Data||2021|
|Projected Data||2021 - 2026|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Segments covered||product type, application, region|
|Regional scope||North America; Europe; Asia Pacific; Central & South America; Middle East & Africa|
|Country Scope||U.S.; Canada; Mexico; Germany; France; U.K.; China; Japan; South Korea; Singapore; Malaysia; Brazil; Saudi Arabia|
|Customization scope||Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.|
|Pricing and purchase options||Avail customized purchase options to meet your exact research needs. Explore purchase options|
The increasing case of cancer at the global level is the major growth driving the global market of adjuvant oncology treatment. Along with this many positive initiatives taken by the governments and insurance companies for paying the treatment cost of cancers that has provided a major boost to the adjuvant market. Moreover, an increasing drive on research initiatives and efforts to discover more diseases that could be treated with adjuvant therapy is about to stimulate the adjuvant market growth in the forecast period.
Based on the types of disease, the adjuvant market is segmented into sarcoma, breast cancer, Hodgkin’s lymphoma, colorectal cancer, glioblastoma, prostate cancer, lung cancer, and ovarian cancer. On the basis of applications, the adjuvant market is divided into immunotherapy, chemotherapy, radiotherapy, and others. In terms of revenue, breast cancer accounted for the significant growth of the market. Also, colorectal cancer will overtake all other segments in the forecast period.
North America and Europe are dominating the market growth of adjuvant. This is due to the high incidences of cancer in the two continents. The greater means of people to spend on quality healthcare, positive reimbursements policies by the government, developed healthcare facilities are some major factors driving the markets. According to World Health Organization (WHO), 75% of countries across the globe have reported having an availability of cancer treatment services which consist of subsidized chemotherapy, cancer surgery, and cancer centers or department. In Europe, a remarkable 90% of countries reported having these cancer treatment services usually available.
Also, Asia Pacific is developing in terms of market share. The rising economies of India and China with their huge populations are key growth drivers. Increasing cases of cancer and developing healthcare infrastructure along with the increase in medical tourism in the region have boosted the adjuvant market growth so far.
Some major manufacturers in the adjuvant market cover BMS, Biogen, Sanofi, AstraZeneca PLC, Eli Lilly Co., Pfizer, Inc, and Amgen, Inc.
For example, in October 2020, Eli Lilly Co. declared that the National Institutes of Health (NIH) ACTIV-3 clinical trial estimating its monoclonal antibody, bamlanivimab (LYCoV555), found that bamlanivimab was not effective in treating people hospitalized with COVID-19. Moreover, in April 2021, the FDA revoked the use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when handled alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain infants.
The increasing case of cancer at global level is the major growth driving the global market of adjuvant oncology treatment. Along with this many positive initiatives taken by the governments and insurance companies for paying the treatment cost of cancers that has provided a major boost to the adjuvant market.
The global demand for the adjuvant market was estimated at approximately USD 760.3 Million in 2020 and is expected to generate revenue of around USD 1,800.6 Million by end of 2026, growing at a CAGR of around 11.1% between 2021 and 2026.
North America and Europe are dominating the market growth of adjuvant. This is due to the high incidences of cancer in the two continents.
Some major manufacturers in the adjuvant market cover BMS, Biogen, Sanofi, AstraZeneca PLC, Eli Lilly Co., Pfizer, Inc, and Amgen, Inc. It studies the sales, revenues, market shares, and growth prospects of each of the players, besides throwing light on their key strategies.